<DOC>
	<DOC>NCT01916993</DOC>
	<brief_summary>The purpose of this research study is to: test the safety, tolerability, and pharmacokinetics (PK testing, the study of how the body absorbs, distributes, breaks down and eliminates a drug) of a single dose of the investigational study drug NBI-98854 in subjects with normal hepatic function or mild, moderate, or severe hepatic impairment.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Male or female, 18 to 75 years of age. Healthy volunteers must be in good general health. Subjects with hepatic impairment must be judged to be in stable condition. Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study. Female subjects must not be pregnant, given birth within 1 year of study start, or breastfeeding. Have a body mass index (BMI) of 18 to 40 kg/m2 (both inclusive). Report more than two alcoholic beverages daily or more than 14 alcoholic beverages weekly withing 7 days of study start. Have a known history of neuroleptic malignant syndrome. Have a positive human immunodeficiency virus (HIV) antibody result at screening or have a history of positive result. Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI98854) during the study. Have an allergy, hypersensitivity, or intolerance to tetrabenazine. Had a blood loss greater than or equal to 500 mL or donated blood within 56 days of study start. Have had previous exposure with NBI98854.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>